Biomarkers and Choroidal Neovascularization
Recruiting now
Conditions studied: Choroidal Neovascularization, Mineralocorticoid Excess
In brief
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Key facts
- Study ID
- NCT04439708
- Run by
- Institut National de la Santé Et de la Recherche Médicale, France
- People needed
- 250
- Starts
- 2020-07-06
- Expected to finish
- 2027-07-06
- Last updated by the study team
- 2026-07-07
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients of group 1:
- Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration
- Patients without intravitreal injection or last intravitreal injection > 3 months
- Informed signed consent
- Patients of group 2:
- Patients without choroidal neovascularization
- Patients with intraocular surgery (cataract or vitrectomy surgery)
- Signed consent
You may not qualify if…
- Myocardial infarction < 12 months
- Chronic renal failure
- Inflammatory disease
- Infectious disease :HIV, viral hepatitis, tuberculosis
- Type 1 or 2 Diabetes
- Patients treated by mineralocorticoid antagonist treatment.
- Type 2 or 3 choroidal neovascularization
- Pregnant woman
Where it is running
- Ophtalmopole Hôpital Cochin — Paris, France (enrolling)
- Hôpital Foch — Suresnes, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.